There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
NCT05924243
Recruiting
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
06/07/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease
Register for Updates
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
NCT05619744
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Small Cell Lung Cancer, Neuroendocrine Carcinoma
Register for Updates
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
NCT05755711
Recruiting
Post-market, prospective, multi-center, single-arm observational study to generate real-world clinical evidence associated with coronary IVL in a population of female subjects with calcified coronary artery disease.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Centennial Heart, Nashville, Tennessee +1 locations
Conditions: Coronary Artery Disease
Register for Updates
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
NCT04647214
Recruiting
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Vanderbilt University Medical Center /ID# 244577, Nashville, Tennessee
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150
Recruiting
The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/06/2024
Locations: Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Chronic Hepatitis B
Register for Updates
First In Human Study of CX-2051 in Advanced Solid Tumors
NCT06265688
Recruiting
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Sarah Cannon Research Institute, LLC, Nashville, Tennessee
Conditions: Solid Tumor, Adult
Register for Updates
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
NCT04801589
Recruiting
Ventilated pediatric patients are frequently over-sedated and the majority suffer from delirium, a form of acute brain dysfunction that is an independent predictor of increased risk of dying, length of stay, and costs. Universally prescribed sedative medications-the GABA-ergic benzodiazepines-worsen this brain organ dysfunction and independently prolong duration of ventilation and ICU stay, and the available alternative sedation regimen using dexmedetomidine, an alpha-2 agonist, has been shown t... Read More
Gender:
All
Ages:
Between 44 weeks and 11 years
Trial Updated:
06/06/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Delirium, Critical Illness, Sedation Complication, Executive Dysfunction, Post Traumatic Stress Disorder
Register for Updates
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee +2 locations
Conditions: Renal Cell Carcinoma
Register for Updates
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402
Recruiting
A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Register for Updates
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04612751
Recruiting
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Research Site, Nashville, Tennessee
Conditions: Advanced or Metastatic NSCLC
Register for Updates
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
06/06/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Single Ventricle Heart Disease
Register for Updates
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
NCT05526521
Recruiting
This is a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study is to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details include: Screening: 2 to 4 weeks; The treatment duration will be 24 weeks; Follow-up period: 12 weeks; The study duration will be 38 to 40 weeks (including screening and follow-up); The number of study visits will be 6.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
06/06/2024
Locations: Monroe Carell Jr. Childrens Hospital at Vanderbilt Site Number : 8400005, Nashville, Tennessee
Conditions: Chronic Spontaneous Urticaria
Register for Updates